Identifying Patients with an Unfavorable Prognosis in Early Stages of Colorectal Carcinoma
Overview
Authors
Affiliations
Background: In recent years, the concept of liquid biopsy diagnostics in detection and progress monitoring of malignant diseases gained significant awareness. We here report on a semi-quantitative real-time cytokeratin 20 RT-PCR-based assay, for detecting circulating tumor cells within a fraction of peripheral blood mononuclear cells in colorectal cancer patients.
Methods: In total, 381 patients were included. Prior to surgical tumor resection, a peripheral blood sample was drawn. Mononuclear cells were isolated by Ficoll centrifugation and a cytokeratin 20 qRT-PCR assay was performed. Quantitative PCR data was assessed regarding histopathological characteristics and patients´ clinical outcome.
Results: A cut-off value was determined at ≥ 2.77 [EU]. Stratifying patients by this cut-off, it represents a statistically highly significant prognostic marker for both the overall and disease-free survival in the entire cohort UICC I-IV (both p<0.001) and in early tumor stages UICC I+II (overall survival p=0.003 and disease-free survival p=0.005). In multivariate analysis, the cut-off value stands for an independent predictor of significantly worse overall and disease-free survival (p=0.035 and p=0.047, respectively).
Conclusion: We successfully established a highly sensitive real-time qRT-PCR assay by which we are able to identify colorectal cancer patients at risk for an unfavorable prognosis in UICC I and II stages.
Richter F, Roder C, Moller T, Egberts J, Becker T, Sebens S Cancers (Basel). 2022; 14(5).
PMID: 35267585 PMC: 8909540. DOI: 10.3390/cancers14051279.
Born J, Hendricks A, Hauser C, Egberts J, Becker T, Roder C Cancers (Basel). 2022; 14(1).
PMID: 35008210 PMC: 8750406. DOI: 10.3390/cancers14010047.
Hendricks A, Dall K, Brandt B, Geisen R, Roder C, Schafmayer C Front Oncol. 2021; 11:646885.
PMID: 34262858 PMC: 8273730. DOI: 10.3389/fonc.2021.646885.
Hendricks A, Brandt B, Geisen R, Dall K, Roder C, Schafmayer C Cancers (Basel). 2020; 12(9).
PMID: 32947903 PMC: 7563529. DOI: 10.3390/cancers12092643.
Zhou T, Wu L, Wang Q, Jiang Z, Li Y, Ma N Oncol Lett. 2018; 16(6):6940-6949.
PMID: 30546426 PMC: 6256417. DOI: 10.3892/ol.2018.9506.